Current Management of Oligometastatic Lung Cancer and Future Perspectives
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 16348
Special Issue Editor
Special Issue Information
Dear Colleagues,
The role of local consolidative treatment (LCT) in the management of patients with oligometastatic IV lung cancer is undergoing serious discussion within multidisciplinary oncologic groups. In particular, in patients with less than five extra-thoracic metastases in less than three organs, LCT—inclusive of surgery for primary lung tumor, lymph nodes and/or metastases as indicated—has proven to be a significant contributing factor to improve progression-free survival in patients with oligometastatic disease after first-line chemotherapy, with or without maintenance treatment (Gomez, Lancet Oncol 2016). At least one more RCT (Iyengar JAMA Oncol 2018), as well as several surgical retrospective studies, have corroborated these findings (Opitz, EJTCS 2020; Mitchell, JTCVS 2020 and Clin Lung Cancer 2020). Furthermore, the recent evidence from the COMET (Palma, Lancet 2019) trial may have shed a new light on the role of SBRT. This Special Issue is aimed at presenting the previous evolution, the current indication and approaches, as well as future perspectives of LCT on the management of oligometastatic disease by involving the real experts in the field as authors.
Prof. Dr. Gaetano RoccoGuest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oligometastatic lung cancer
- local consolidative treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.